Oli Denne

Cambridge UK

Contact Me Today

Oli is a senior associate in our Cambridge office and is part of the Corporate Technology team.

Oli advises a range of companies in the tech and life sciences sectors on a variety of corporate matters, including venture capital investments, fundraisings, M&A and joint ventures.

CV

Since 2023 Senior Associate, Taylor Wessing

2021 - 2023 Associate, Taylor Wessing

2019 - 2020 Associate, Slaughter and May

Career

Since 2023 Senior Associate, Taylor Wessing

2021 - 2023 Associate, Taylor Wessing

2019 - 2020 Associate, Slaughter and May

Education

2019 Admitted as a solicitor in England & Wales

2016 - 2017 GDL & LPC, BPP Law School

2012 - 2015 BA Politics, University of Warwick

Experience

Advising on Draig Therapeutics' US$140 million series A financing

We have advised a syndicate of leading global life sciences investors including Access Biotechnology, Canaan Partners and SR One on their landmark US$140 million series A investment in Draig Therapeutics.

Press release

Ross McNaughton

Elinor Picton

Oli Denne

Helen Farr

Adrian Toutoungi

Charlie Adams

Nicholas Vollers

Ed Chapman

Healx raises $47 million in its Series C funding

Advised Healx, an AI-enabled, clinical-stage biotech company specializing in rare diseases based in Cambridge UK, on its $47 million Series C funding. The funding was co-led by Silicon Valley-based R42 Group and Atomico, one of Europe’s largest venture capital firms, with participation from new and existing investors including Balderton, Jonathan Milner, Global Brain, btov, Ayana Capital, o2h and VU Venture Partners.

Press release

Ross McNaughton

Oli Denne

Colin McCall

Apollo Therapeutics closes $226.5 million series C financing

We advised Apollo Therapeutics in their USD226.5 million series C fundraising. Apollo aims to advance pipeline programs through clinical development and further fund the company’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, which include The Institute of Cancer Research.

Press release

Andrew Edge

Howard Palmer

Oli Denne

Charlie Adams

Advising Biomodal

Advising Biomodal (formerly Cambridge Epigenetix) on its US$88 million Series D funding round to advance best-in-class DNA sequencing technology platform

Press release

Ross McNaughton

Oli Denne